Unternehmensprofil der M1 Kliniken AG
Unternehmensprofil der M1 Kliniken AG

Unique business model

Company profile

M1 Kliniken AG, based in Berlin, is one of the fastest growing and leading private providers of health services in the beauty sector. With its products and services, the group of companies with more than 200 employees offers a customer-oriented spectrum of aesthetic and surgical treatments throughout Germany. Our experienced and highly specialised team uses high-quality products and state-of-the-art medical technology to perform more than 240,000 minimally invasive and surgical procedures every year to the highest quality standards.

Business model

With the guiding principle "highest quality at the best price", M1 started in 2012 and has established itself as the market leader for beauty medicine in Germany. M1 aims to achieve this leading position in the international beauty segment as well by constantly expanding abroad.

To realize this vision, M1 has developed a unique business model, which is based on specialisation and thus providing the highest quality in medicine. Experts agree on this and for us, top medicine through specialisation is the corporate DNA. M1 Kliniken is the first company to focus on selected treatments within aesthetic and plastic medicine. The results are economies of scale and affordable prices.

More than 90 highly specialized doctors perform more treatments in their field of specialty than regular doctors. This routine increases safety for our clients. Our own training and further education at the M1 Akademie also contributes to this. At the same time, centralised purchasing enables us to use the most modern technical infrastructure and the highest quality products and medicines at attractive prices. With this specialisation, M1 makes top medicine accessible to the general public.

> 350 employees

340,000 treatments annually

> 50 specialist centres worldwide

100 specialist centres by 2024

Latest news

| Investor News

  • Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions
  • Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)
  • The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.

| Investor News

M1 Kliniken AG publishes preliminary figures for the 2021 financial year. In the past financial year, the M1 Group was able to significantly expand its market position in the field of beauty medicine and opened seven new specialist centres in the German home market alone. The subsidiary Haemato AG set a cornerstone for the development of the own-brand business with the in-licensing of a botulinum toxin product from Huons Biopharma. The start of the clinical approval trial is planned for the second half of 2022.

| Investor News

  • Average daily sales in November 2021 in the German practice network again at record level
  • All specialist centres open
  • With four more openings in Germany and Australia, M1 will operate a total of 47 specialty centres by year-end 2021

| Investor News

  • Group revenue rises to EUR 237 million (EUR 82 million in Q3-2020)
  • Beauty: treatment numbers at high level; record revenue in German practice network in October 2021; no negative impact from rising incidence rate of the Corona pandemic
  • Group EBITDA amounts to EUR 13.3 million (previous year: EUR 8.8 million); EBIT amounts to EUR 9.1 million (previous year: EUR 5.8 million); EBIT margin in the German practice network in the target corridor of 15-20% despite large number of new openings